Mondegobio
Cantanhede, PT · 1 known investors
Mondego Bio develops PTPN2 (protein tyrosine phosphatase non-receptor type 2) inhibitors as immuno-oncology therapies, aiming to enhance IFNγ signaling to make tumor cells more susceptible to immune attack. The company focuses on small-molecule cancer immunotherapy drug candidates with oral bioavailability and improved safety profiles.
BiotechHealthtech
Investors · 1
Frequently asked questions
- What does Mondegobio do?
- Mondego Bio develops PTPN2 (protein tyrosine phosphatase non-receptor type 2) inhibitors as immuno-oncology therapies, aiming to enhance IFNγ signaling to make tumor cells more susceptible to immune attack. The company focuses on small-molecule cancer immunotherapy drug candidates with oral bioavailability and improved safety profiles.
- Who are Mondegobio's investors?
- Mondegobio's investors include OrbiMed.
- Where is Mondegobio headquartered?
- Mondegobio is headquartered in Cantanhede, PT.